Last reviewed 2026-05-27 · How we verify

EryDex Low dose DSP

Quince Therapeutics S.p.A. · Phase 3 active Small molecule Under review Quality 0/100

EryDex Low dose DSP is a Corticosteroid Small molecule drug developed by Quince Therapeutics S.p.A.. It is currently in Phase 3 development for Inflammatory and autoimmune conditions (specific indication under investigation in Phase 3). Also known as: EryDex System end product.

EryDex Low dose DSP is a dexamethasone-based formulation designed to deliver corticosteroid therapy at reduced systemic doses while maintaining local therapeutic effect.

EryDex Low dose DSP is a small molecule that blocks the sodium channel protein type 9 subunit alpha. It is being studied in clinical trials for the treatment of nervous system diseases and genetic syndromes, including ataxia telangiectasia.

Likelihood of approval

59.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Immunology slight uplift +1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	EryDex Low dose DSP
Also known as	EryDex System end product
Sponsor	Quince Therapeutics S.p.A.
Drug class	Corticosteroid
Target	Glucocorticoid receptor
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 3

Mechanism of action

The drug combines dexamethasone with a drug-specific delivery system (DSP) technology to optimize pharmacokinetics and reduce systemic exposure. This approach aims to preserve anti-inflammatory and immunosuppressive efficacy while minimizing corticosteroid-related adverse effects associated with higher systemic doses.

Approved indications

Inflammatory and autoimmune conditions (specific indication under investigation in Phase 3)

Common side effects

Hyperglycemia
Hypertension
Immunosuppression
Insomnia

Key clinical trials

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EryDex Low dose DSP CI brief — competitive landscape report
EryDex Low dose DSP updates RSS · CI watch RSS
Quince Therapeutics S.p.A. portfolio CI

Frequently asked questions about EryDex Low dose DSP

What is EryDex Low dose DSP?

EryDex Low dose DSP is a Corticosteroid drug developed by Quince Therapeutics S.p.A., indicated for Inflammatory and autoimmune conditions (specific indication under investigation in Phase 3).

How does EryDex Low dose DSP work?

EryDex Low dose DSP is a dexamethasone-based formulation designed to deliver corticosteroid therapy at reduced systemic doses while maintaining local therapeutic effect.

What is EryDex Low dose DSP used for?

EryDex Low dose DSP is indicated for Inflammatory and autoimmune conditions (specific indication under investigation in Phase 3).

Who makes EryDex Low dose DSP?

EryDex Low dose DSP is developed by Quince Therapeutics S.p.A. (see full Quince Therapeutics S.p.A. pipeline at /company/quince-therapeutics-s-p-a).

Is EryDex Low dose DSP also known as anything else?

EryDex Low dose DSP is also known as EryDex System end product.

What drug class is EryDex Low dose DSP in?

EryDex Low dose DSP belongs to the Corticosteroid class. See all Corticosteroid drugs at /class/corticosteroid.

What development phase is EryDex Low dose DSP in?

EryDex Low dose DSP is in Phase 3.

What are the side effects of EryDex Low dose DSP?

Common side effects of EryDex Low dose DSP include Hyperglycemia, Hypertension, Immunosuppression, Insomnia.

What does EryDex Low dose DSP target?

EryDex Low dose DSP targets Glucocorticoid receptor and is a Corticosteroid.

Drug class: All Corticosteroid drugs
Target: All drugs targeting Glucocorticoid receptor
Manufacturer: Quince Therapeutics S.p.A. — full pipeline
Therapeutic area: All drugs in Immunology
Indication: Drugs for Inflammatory and autoimmune conditions (specific indication under investigation in Phase 3)
Also known as: EryDex System end product

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing